Investigation of the effects of the blood plasma levels of C16 ceramides on the course of non-alcoholic fatty liver disease
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 5
Abstract
Objective — to investigate the dependence of the blood plasma levels of C16 ceramides on the degree of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) based on the results of steatomometry in comparison with healthy subjects. Materials and methods. The study involved 20 patients with NAFLD and 20 healthy people. Among them, 10 (50 %) were men and 10 (50 %) women. The mean age of patients was 50.2 ± 1.93 years. The mean body weight in the main group was 103.5 ± 1.9 kg, and the mean BMI was 33.1 ± 0.5. The men blood glucose level was 5.6 ± 0.1 mmol/L; HOMA index 2.4 ± 0.2. The results of steatometry showed the mean damping factor of 2.70 ± 0.2, which corresponded to S2 degree of liver steatosis. NAFLD diagnosis was verified based on patient’s complaints, anamnesis of the disease, objective examination including anthropometric parameters, laboratory methods (blood glucose, glycosylated hemoglobin, HOMA index), parameters of steatometry, elastometry and mass spectrometry liquid chromatography (Shimadzu Nexera X2 UHPLC, Shimadzu LCMS-8045 mass spectrometer). The control group consisted of 20 healthy age- and gender-matching subjects with normal body mass. Results. NAFLD patients demonstrated the significantly increased blood plasma levels of C16 ceramides up to 0.402 ± 0.01 μmol/L, compared to healthy subjects levels of 0.271 ± 0.01 μmol/L (p < 0.001), that corresponded to a moderate steatosis degree. The glucose levels and NOMA index in NAFLD patients were within the normal limits of 5.6 ± 0.1 mmol/L and 2.4 ± 0.2, respectively. Conclusions. The elevated blood plasma levels of C16 ceramides significantly (p < 0.001) affected the degree of steatosis compared to the healthy people, they proved to be more sensitive marker of insulin resistance.
Authors and Affiliations
L. L. Pavlovskyi, V. V. Chernyavskyi, V. P. Shipulin, L. M. Kupchyk
Keywords
Related Articles
- EP ID EP675095
- DOI 10.30978/MG-2019-5-14
- Views 113
- Downloads 0
Age-related and hormonal and metabolic peculiarities of patients with non-alcoholic fatty liver disease in combination with subclinical hypothyroidism
Objective — to identify age-related and hormonal and metabolic features in patients with non-alcoholic fatty liver disease (NAFLD) in combination with subclinical hypothyroidism (SH). Materials and methods. The study in...
Complex treatment of non-alcoholic fatty liver disease: experience of the use of hepatoprotectors
Objective — to evaluate the complex therapy effects at the levels of cytokeratin (CK)-18, fibroblast growth factor (FGF)-21 and metabolic parameters of nonalcoholic fatty liver disease (NAFLD) patients. Materials and...
Nutrigenetic characteristics of patients with nonalcoholic liver disease combined with metabolic syndrome
Objective — to detect possible association of polymorphisms of the Pro12Ala of PPARG2 gene (rs1801282) and ADRB3 gene (rs4994) with a degree of fatty liver and metabolic disorders in patients with NAFLD. Materials and m...
Gastrointestinal involvement in systemic sclerosis: diagnostic and therapeutic aspects
Systemic sclerosis (SSc) is a rare autoimmune disorder that carries a high morbidity and mortality. It is characterized by fibrosis of multiple organs including skin, musculoskeletal system, the lungs, kidneys, heart and...
Selection of hepatoprotector in multimorbid diseases of hepatobiliary system
Objective — to study of the efficacy and tolerability of Artigel complex in the treatment of patients suffering from non-alcoholic fatty liver disease (NAFLD) in combination with chronic acalculous cholecystitis (CAC) wi...